Structure Therapeutics INC Form 4 insider transactions

Xichen Lin, Chief Scientific Officer of Structure Therapeutics, exercised a share option, converted ordinary shares into American Depositary Shares (ADS), and sold a portion of these ADS under a pre-arranged Rule 10b5-1 trading plan.

FMR LLC, along with related entities and individuals, reports changes in beneficial ownership of Structure Therapeutics Inc. ordinary shares and American Depositary Shares.

Xichen Lin, Chief Scientific Officer of Structure Therapeutics, files an amendment to a previous SEC Form 4 to correct the exercise price of stock options.

Mark Allen Bach, Chief Medical Officer of Structure Therapeutics Inc., files an amendment to a Form 4, correcting the exercise price of stock options to reflect the price of Ordinary Shares rather than American Depositary Shares (ADSs).

Ma Yingli, Chief Technology Officer of Structure Therapeutics Inc., files an amendment to a Form 4, correcting the exercise price of stock options to reflect the price of Ordinary Shares rather than American Depositary Shares.

Jun Yoon, CFO of Structure Therapeutics, files an amendment to a Form 4, correcting the stock option exercise price to reflect the price of Ordinary Shares rather than American Depositary Shares (ADSs).

Raymond C. Stevens, CEO of Structure Therapeutics, filed an amendment to a Form 4, correcting the exercise price of stock options to reflect the price of Ordinary Shares rather than American Depositary Shares (ADSs).

Xichen Lin, Chief Scientific Officer of Structure Therapeutics, was granted stock options and restricted stock units on March 15, 2024.

Yingli Ma, Chief Technology Officer of Structure Therapeutics Inc., reports acquisition of stock options and restricted stock units.

Mark Allen Bach, Chief Medical Officer of Structure Therapeutics Inc., was granted stock options and restricted stock units (RSUs) on March 15, 2024.

Jun Yoon, CFO of Structure Therapeutics, reports the acquisition of restricted stock units and stock options, along with adjustments to beneficial ownership of ordinary shares.

Raymond Stevens, CEO of Structure Therapeutics Inc., reports acquisition of restricted stock units and stock options, impacting his beneficial ownership of ordinary shares.

FMR LLC, along with related entities and individuals, reports changes in beneficial ownership of Structure Therapeutics Inc. securities, including American Depositary Shares and Ordinary Shares.